Compare Sanofi (SNY) vs Johnson & Johnson (JNJ) Stock

Sanofi (SNY) offers the better valuation at 20.3x trailing P/E (11.5x forward), making it the more compelling value choice. Analysts rate Sanofi (SNY) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Sanofi (SNY) is the cheapest at 20.3x versus Johnson & Johnson at 42.9x. On forward P/E, Sanofi is actually cheaper at 11.5x.

Over the past 5 years, Johnson & Johnson (JNJ) delivered a total return of +70.8%, compared to +28.0% for Sanofi (SNY). A $10,000 investment in JNJ five years ago would be worth approximately $17K today (assuming dividends reinvested). Over 10 years, the gap is even starker: JNJ returned +175.7% versus SNY's +70.2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.06β versus Sanofi's 0.35β — meaning SNY is approximately 532% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Sanofi (SNY) carries a lower debt/equity ratio of 30% versus 51% for Johnson & Johnson — giving it more financial flexibility in a downturn.

Sanofi (SNY) is the more profitable company, earning 16.7% net margin versus 15.8% for Johnson & Johnson — meaning it keeps 16.7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: JNJ leads at 24.9% versus 13.6% for SNY. At the gross margin level — before operating expenses — SNY leads at 72.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Sanofi (SNY) trades at 11.5x forward P/E versus 21.5x for Johnson & Johnson — 10.0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SNY: 17.2% to $57.02.

In this comparison, JNJ (2.0% yield) pays a dividend. SNY does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Johnson & Johnson (JNJ) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.06), 2.0% yield, +175.7% 10Y return). Both have compounded well over 10 years (JNJ: +175.7%, SNY: +70.2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. JNJ pays a dividend while SNY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.